Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
Authors
Keywords
Simvastatin, Ezetimibe, Familial Hypercholesterolemia, Mipomersen, Homozygous Familial Hypercholesterolemia
Journal
CLINICAL PHARMACOKINETICS
Volume 54, Issue 2, Pages 133-146
Publisher
Springer Nature
Online
2015-01-05
DOI
10.1007/s40262-014-0224-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lomitapide and Mipomersen
- (2014) Daniel J. Rader et al. CIRCULATION
- Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects
- (2014) Zhaoyang Li et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Lack of Clinical Pharmacodynamic and Pharmacokinetic Drug–Drug Interactions Between Warfarin and the Antisense Oligonucleotide Mipomersen
- (2014) Zhaoyang Li et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces LDL-C in HoFH Pediatric Patients†
- (2014) Sheryl Selvey et al. Journal of Clinical Lipidology
- Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers
- (2014) JoAnn D. Flaim et al. Journal of the American Heart Association
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
- (2013) Mark J. Graham et al. CIRCULATION RESEARCH
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Long Term Efficacy and Safety of Mipomersen During 4 Years of Treatment in a Cohort of Patients with Heterozygous Familial Hypercholesterolemia and Coronary Artery Disease (CAD)
- (2013) P. Bart Duell et al. Journal of Clinical Lipidology
- JCL Roundtable: Drug treatment of severe forms of familial hypercholesterolemia
- (2013) W. Virgil Brown et al. Journal of Clinical Lipidology
- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
- (2013) Gregory S. Thomas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
- (2012) Frederick J. Raal et al. ATHEROSCLEROSIS
- Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B
- (2012) Stanley T. Crooke et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
- (2012) Evan A. Stein et al. CIRCULATION
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Clinical pharmacokinetics of second generation antisense oligonucleotides
- (2012) Rosie Z Yu et al. Expert Opinion on Drug Metabolism & Toxicology
- Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins
- (2012) S. Matthijs Boekholdt et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease
- (2012) Sotirios Tsimikas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
- (2012) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
- (2012) Mary P. McGowan et al. PLoS One
- A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans
- (2012) Nicholas R Jones et al. Molecular Therapy-Nucleic Acids
- Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy
- (2011) Frederick J. Raal et al. CIRCULATION
- A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
- (2011) Allan D. Sniderman et al.
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
- (2011) Anne C. Goldberg et al. Journal of Clinical Lipidology
- Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
- (2010) Fatima Akdim et al. AMERICAN JOURNAL OF CARDIOLOGY
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
- (2010) C. Frank Bennett et al. Annual Review of Pharmacology and Toxicology
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
- (2010) Fatima Akdim et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- In Vitro Metabolic Stabilities and Metabolism of 2′-O-(Methoxyethyl) Partially Modified Phosphorothioate Antisense Oligonucleotides in Preincubated Rat or Human Whole Liver Homogenates
- (2010) Min-Son Baek et al. OLIGONUCLEOTIDES
- Antisense oligonucleotide pharmacokinetics and metabolism
- (2009) Richard S Geary Expert Opinion on Drug Metabolism & Toxicology
- Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
- (2008) Rosie Z. Yu et al. BIOCHEMICAL PHARMACOLOGY
- Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
- (2008) Rosie Z Yu et al. CLINICAL PHARMACOKINETICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started